Gefitinib

Drug Profile

Gefitinib

Alternative Names: Iressa; ZD 1839

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Brigham and Women's Hospital; Dana-Farber Cancer Institute; Hutchison MediPharma; Massachusetts General Hospital; MedImmune; Netherlands Cancer Institute; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Morpholines; Phenyl ethers; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Colorectal cancer; Salivary gland cancer
  • Phase I Head and neck cancer
  • Discontinued Bladder cancer; Brain metastases; Breast cancer; Glioblastoma; Renal cell carcinoma; Thyroid cancer

Most Recent Events

  • 01 Sep 2016 AstraZeneca in collaboration with M D Anderson Cancer Center completes a phase II clinical trial in Salivary gland cancer (Late-stage disease, Metastatic disease, Recurrent) in USA (PO) (NCT00509002)
  • 01 Jun 2016 AstraZeneca completes its phase IIa trial for Non-small cell lung cancer (Combination therapy, Late-stage disease) in USA (NCT02179671)
  • 30 Apr 2016 AstraZeneca completes phase-II/III clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, First-line therapy) in Netherlands, United Kingdom, Australia, Czech Republic, Ireland, Canada (PO) (NCT00259064; EudraCT2004-004206-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top